StockNews.com Initiates Coverage on vTv Therapeutics (NASDAQ:VTVT)

Equities researchers at StockNews.com started coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a report released on Wednesday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Alliance Global Partners assumed coverage on shares of vTv Therapeutics in a report on Monday, December 9th. They issued a “buy” rating and a $35.00 price target for the company.

vTv Therapeutics Price Performance

Shares of VTVT opened at $17.60 on Wednesday. vTv Therapeutics has a 1-year low of $12.12 and a 1-year high of $30.99. The company has a 50-day moving average of $16.92 and a 200 day moving average of $15.44. The firm has a market capitalization of $56.14 million, a price-to-earnings ratio of -3.89 and a beta of 1.07.

vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings results on Thursday, March 20th. The biotechnology company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.32. The business had revenue of $0.02 million during the quarter.

Institutional Trading of vTv Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. FMR LLC acquired a new position in vTv Therapeutics during the third quarter worth $2,402,000. JPMorgan Chase & Co. acquired a new position in vTv Therapeutics during the fourth quarter worth $25,000. Finally, Geode Capital Management LLC raised its position in vTv Therapeutics by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company’s stock worth $158,000 after acquiring an additional 1,327 shares during the period. 17.51% of the stock is owned by hedge funds and other institutional investors.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.